Investigational drug · Phase 3
Molnupiravir
Also called: MK-4482, LAGEVRIO
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Coronavirus Disease (COVID-19).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
31
Any phase or sponsor naming "Molnupiravir"
First trial start
2024
Dec 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Molnupiravir", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Coronavirus Disease (COVID-19)
Approved drugs for the same conditions: COVID-19 · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Molnupiravir" as an intervention, largest first.
Charles University, Czech RepublicAcademic, hospital or other
NCT07720596 · 1,795,570 participants · Start Jan 1, 2022 · Primary completion Dec 31, 2024
Drug: Molnupiravir · For: COVID-19; SARS-CoV-2
Sites: Prague, Czechia
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05041907 · 3,800 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 2027
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide and 16 more · For: COVID-19
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 7 sites in all
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06667700 · 3,082 participants (planned) · Start Dec 2, 2024 · Primary completion Jan 26, 2031
Drug: Molnupiravir; Placebo · For: Coronavirus Disease (COVID-19)
Sites: Cullman, Alabama; Paradise Valley, Arizona; Phoenix, Arizona · 230 sites in all
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05648448 · 3,000 participants (planned) · Start Feb 22, 2023 · Primary completion Jan 1, 2027
Drug: Oseltamivir; Favipiravir and 8 more · For: Influenza; Influenza, Human
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 4 sites in all
- Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.Status unknown
Serap YavuzAcademic, hospital or other
NCT06223932 · 2,600 participants (planned) · Start Jul 7, 2022 · Primary completion Feb 2024
Drug: Molnupiravir · For: COVID-19; SARS-CoV-2 Infection
Sites: Istanbul, Turkey (Türkiye); Ankara, Turkey (Türkiye) · 8 sites in all
- Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04939428 · 2,441 participants · Start Aug 11, 2021 · Primary completion Nov 16, 2022
Drug: Molnupiravir; Placebo · For: Coronavirus Disease (COVID-19)
Sites: Birmingham, Alabama; Mesa, Arizona; Tucson, Arizona · 226 sites in all
PregistryIndustry
NCT05013632 · 2,000 participants (planned) · Start Dec 1, 2021 · Primary completion Sep 30, 2027
Drug: Antiviral Agents; Monoclonal antibody · For: Covid19
Sites: Los Angeles, California
- Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04575597 · 1,735 participants · Start Oct 19, 2020 · Primary completion May 5, 2022
Drug: Molnupiravir; Placebo · For: Coronavirus Disease (COVID-19)
Sites: Peoria, Arizona; Los Angeles, California; North Hollywood, California · 173 sites in all
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
NCT05195060 · 1,178 participants · Start Dec 14, 2021 · Primary completion Sep 1, 2025
Drug: casirivimab with imdevimab; sotrovimab and 1 more · For: COVID-19
Sites: Amsterdam, Netherlands; Leiden, Netherlands; Nijmegen, Netherlands · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Medico-legal integration of molnupiravir rapid deployment during the COVID-19 pandemic: Emergency use authorization, clinical evidence, and risk of viral mutagenesis.
Tsai TH · One Health 2026
- Antiviral activities of multiple antivirals against highly pathogenic avian influenza A H5N1 in vitro and in mice.
Liu D, Fan Y, Leung KY, et al. · Emerg Microbes Infect 2026
- Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix.
Borriello F, Koh GCKW, Troconiz IF, et al. · J Infect Dis 2026
- Dual prodrugs of N4-hydroxycytidine with ProTide and ester modifications as anti-SARS-CoV-2 agents.
Li Y, Zhang W, Gao N, et al. · Eur J Med Chem 2026
- Baloxavir and molnupiravir protect against severe influenza A(H5N1) infection in immunosuppressed hamsters.
Arroyave A, Rabezanahary H, Sahli A, et al. · PLoS Pathog 2026
- Antiviral Activity and Safety of Molnupiravir in Healthy Participants Inoculated With Influenza Virus: A Phase 2a, Randomized, Human Challenge Trial.
Nussbaum J, Mann AJ, Liao LE, et al. · Clin Pharmacol Ther 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.